Decoy disruption of the FOXO4-p53 interaction
FOXO4-DRI is proposed to disrupt the FOXO4-p53 interaction in senescent cells, preventing FOXO4 from sequestering p53 in nuclear bodies and restoring p53's apoptotic role.
FOXO4-DRI research profile with current summaries, safety notes, and reference details.
FOXO4-p53 disruption potency (IC50)
Low- to mid-µM in interaction assays
Measures decoy/interference activity against the FOXO4-p53 interaction.
Cellular FOXO4 pathway suppression
Reduces FOXO4 pro-survival transcriptional output
Functional readout consistent with FOXO4 blockade.
Apoptotic sensitization under stress
Increases apoptosis markers
Tracks stress-dependent cell death after FOXO4-DRI exposure.
Abstract summary
FOXO4-DRI is a D-retro-inverso senolytic peptide that disrupts the FOXO4-p53 interaction in senescent cells. In preclinical models, this releases p53-mediated apoptotic signaling and is used to study senescence clearance, chemotoxicity, and aging-related tissue dysfunction.
Summary notes
FOXO4-DRI is a D-retro-inverso senolytic peptide that disrupts the FOXO4-p53 interaction in senescent cells. By restoring p53-driven apoptotic signaling, it is used in preclinical research to study senescent cell clearance, chemotoxicity, and aging-related tissue dysfunction.
Often discussed for senolytic activity.
Common research note: Published preclinical regimen: 5 mg/kg intraperitoneally in mice, given every other day for three doses (days 1, 3, and 5) in the original Cell study..
FOXO4-DRI is proposed to disrupt the FOXO4-p53 interaction in senescent cells, preventing FOXO4 from sequestering p53 in nuclear bodies and restoring p53's apoptotic role.
Mechanism facets
By interrupting FOXO4-p53 binding, FOXO4-DRI reduces the survival advantage that lets senescent cells persist under stress and supports downstream apoptotic signaling.
Functional interference with FOXO4's pro-survival output reduces survival and stress-response signaling, increasing apoptosis markers and reducing viability in sensitive models.
Study type: single-arm, investigator-initiated translational window-of-opportunity study (human tumor biopsies where feasible) evaluating FOXO4-DRI as an adjunct to a DNA-damaging regimen. Population: adults with FOXO4-high tumors or tumors showing baseline FOXO4 transcriptional signatures; n typically small (target 10–25 evaluable). Intervention: short-course FOXO4-DRI plus standard-of-care chemotherapy (e.g., platinum or topoisomerase inhibitor) with predefined sampling timepoints (pre-dose and on-treatment biopsy or circulating surrogate markers). Signals: increased apoptosis/mitotic catastrophe markers in on-treatment samples (e.g., cleaved PARP/caspase-3, Annexin V-associated signatures) and reduced FOXO4-driven pro-survival transcriptional output (decreased expression of FOXO4-dependent stress-adaptation genes reported in research settings). Evidence quality: mechanistic alignment with FOXO4 dependence (correlational enrichment in FOXO4-high cohorts; dose–response where feasible). Practical interpretation: a consistent on-treatment shift from pro-survival to apoptosis programs supports target engagement/function, but lack of a control arm limits causal inference unless paired with FOXO4-high stratification or pharmacodynamic benchmarking.
Research notes
Study type: translational pharmacodynamic profiling (human blood and/or paired tumor samples). Population: adults with advanced solid tumors receiving investigational FOXO4-DRI monotherapy or in combination; n typically 15–40. Intervention: escalating dosing or optimized schedule to achieve measurable intracellular exposure; paired sampling at trough and post-dose timepoints. Signals: (1) reduction in FOXO4 pro-survival transcriptional reporter activity or endogenous transcriptional signatures; (2) decreased FOXO4 interaction with pro-survival partner proteins assessed by proximity-based assays (e.g., interaction mapping/PLA) or immunoprecipitation-derived interaction metrics from limited tissue; (3) induction of stress-response reversal signatures (rebalancing oxidative-stress and metabolic stress transcription). Evidence quality: moderate-to-high if measured using both (a) interaction-proximal biomarkers and (b) downstream transcriptional/apoptosis readouts at concordant timepoints. Practical interpretation: concordant decrease in FOXO4–partner interaction and FOXO4 transcriptional output is stronger evidence of on-target pharmacology than downstream apoptosis markers alone.
Study type: early clinical safety and formulation-feasibility assessment (Phase 1-like design, dose-escalation). Population: adults with refractory solid tumors; n typically 20–60. Intervention: FOXO4-DRI delivered via a predefined formulation (e.g., peptide-compatible vehicle; delivery optimization emphasized). Signals: tolerability profile focusing on infusion-related reactions, local tolerability, and systemic adverse events; laboratory parameters including inflammatory markers and liver enzymes. Evidence quality: contextual (not efficacy-defining), but directly informs whether serum stability and uptake are adequate for sustained target engagement. Common outcomes: incidence/severity of treatment-emergent adverse events, maximum tolerated dose or recommended Phase 2 dose, and exposure–response trends for pharmacodynamic biomarkers. Practical interpretation: if exposure is insufficient due to rapid degradation, pharmacodynamic signals may be weak even with acceptable safety; conversely, dose-limiting toxicities can constrain achievable pharmacology and must be weighed against the magnitude of FOXO4 pathway inhibition.
FOXO4-DRI is a research-use peptide intended for mechanistic studies. It is not approved for human or veterinary use.
Monitoring
Downstream phenotypes: pro-survival transcriptional program vs apoptosis induction
Track whether inhibiting FOXO4 pro-survival transcriptional output shifts cells toward apoptosis under stress. Readouts: changes in FOXO4 target gene expression (qPCR/RNA-seq or transcriptional reporter), survival/anti-apoptotic marker levels, and apoptosis markers (cleaved caspase-3/7, PARP cleavage, Annexin V/PI, TUNEL). Timeline: 6–24 h for early transcriptional changes; 24–96 h for apoptotic execution and measurable viability loss. Follow-up checkpoints: run stress-context comparisons (e.g., oxidative stress, DNA damage, kinase inhibitor or metabolic stress conditions) to confirm synergy/sensitization; confirm that apoptosis correlates with FOXO4 reporter suppression (and not general toxicity markers from non-specific peptides).
Therapy sensitization / stress-response shift (functional causality)
In relevant models, monitor whether FOXO4-DRI sensitizes to agents that induce stress-adaptive survival. Readouts: combination index or Bliss/Loewe synergy metrics (cell viability/apoptosis), clonogenic survival, cell-cycle changes (flow cytometry), and stress-response pathway markers downstream of the FOXO4 program. Timeline: 24–72 h for viability/apoptosis synergy; 7–14 days for clonogenic endpoint stability. Follow-up checkpoints: use FOXO4 dependency controls (genetic FOXO4 loss-of-function should phenocopy FOXO4-DRI effects; FOXO4 re-expression/rescue should blunt response if feasible). Compare against benchmark inhibitors/known FOXO4 perturbations (where applicable) to ensure mechanism-consistent outcomes.
Pharmacology considerations: serum stability, cellular uptake, and exposure–response
Monitor peptide performance in biologically relevant conditions to interpret efficacy correctly. Readouts: serum stability in relevant media (LC-MS peptide half-life), cellular uptake/retention (labeled peptide tracking), and exposure–response relationships (activity at measured intracellular/extracellular concentrations). Timeline: stability in vitro at defined timepoints (0–24 h); uptake within minutes–hours; functional readouts alongside exposure measurements (commonly 6–96 h). Follow-up checkpoints: if efficacy is weak, distinguish delivery limitations from mechanism failure by correlating (i) uptake/stability metrics with (ii) FOXO4 engagement (co-IP/PLA/reporter suppression). Re-check that formulation changes preserve specific activity and do not induce non-specific cytotoxicity.
Specificity and off-target/toxicity surveillance
Monitor for non-specific effects that could confound interpretation of FOXO4 dependence. Readouts: broad viability/metabolic assays (ATP-based, LDH release), general DNA damage signaling (e.g., γH2AX) unrelated to intended stress context, stress markers not uniquely tied to FOXO4, and cytokine/inflammation proxies if using relevant systems. Include peptide controls: scrambled peptide, vehicle-only, and a concentration-matched non-binding control. Timeline: 24–96 h for acute toxicity screens; longer (up to 14 days) for delayed effects in clonogenic or proliferation assays. Follow-up checkpoints: establish a therapeutic window where FOXO4 reporter/interaction disruption occurs with minimal non-specific toxicity; confirm that phenotypes are reduced by FOXO4 loss/absence of FOXO4 (or strengthened in FOXO4-high models), supporting mechanism specificity.
Administer FOXO4-DRI to target cells (e.g., cancer lines with FOXO4-dependent stress survival) as a dose series spanning ~0.1–10 µM (or the closest practical range based on solubility), keeping exposure time constant (e.g., 4–24 h). Include vehicle and a non-binding/scrambled peptide control. For pathway causality readouts, assess FOXO4 downstream transcriptional outputs (reporter/RT-qPCR), FOXO4 interaction disruption (co-IP/pull-down), and apoptosis/viability markers at the same post-treatment timepoint(s). If toxicity of the peptide alone is observed, narrow to lower concentrations and re-titrate. Consider repeating at 2–3 dose “windows” (low/medium/high) centered on the lowest concentration that produces measurable disruption.
Reference notes
In vitro sensitization schedule (stressor timing)
Use FOXO4-DRI as a pre- and/or co-treatment to probe sensitization to stress or therapy. Example pattern: pre-treat with FOXO4-DRI for ~2–6 h, then add the stressor/therapy (e.g., DNA-damaging agent, oxidative stressor, or kinase inhibitor) and maintain FOXO4-DRI for an additional ~24–48 h. Titrate FOXO4-DRI across ~0.1–10 µM (or a narrower range informed by the mechanistic titration). Evaluate synergy as changes in apoptosis markers and viability relative to stressor-alone and FOXO4-DRI-alone groups. If interaction disruption appears dose-limited, test a second dosing window (e.g., lower dose maintained continuously vs. higher dose pulse) to distinguish timing effects from exposure level.
In vivo exploratory dose escalation (formulation/route dependent)
For initial in vivo studies, run a small dose-escalation cohort to identify a biologically active exposure range. Choose a starting dose conservatively based on prior peptide literature for the intended route (IV vs. IP vs. intratumoral vs. topical/local) and serum-stability/delivery strategy. Implement 3–4 dose levels (e.g., low/medium/high plus a lower sentinel dose) with at least one intermediate dose to refine the dose–response. Administer on a schedule appropriate to the formulation (commonly once daily or every other day for short peptides), with dosing timed to the experimental endpoint (e.g., dosing starts 1–3 days before the stress/therapy challenge and continues through early treatment for target engagement). Collect tissues at early and late timepoints (e.g., 1–6 h post-dose for interaction/transcriptional readouts if feasible; and 24–72 h for apoptosis/biomarkers) to confirm on-target disruption.
Cycle-based regimen for repeat dosing studies (tolerance/efficacy balance)
When multiple dosing cycles are needed (e.g., sustained tumor stress/therapy regimens), use a cycle structure to balance efficacy and potential tolerability. Example: dose FOXO4-DRI for 3–5 consecutive days followed by a 2–5 day drug-free interval, then repeat for 1–3 cycles depending on study design. Maintain consistent dose and timing within each cycle and keep the stressor/therapy dosing window aligned across groups. Monitor pharmacodynamic markers of FOXO4 output (apoptosis markers, stress-response transcriptional signatures) to determine whether breaks are required to maintain target engagement. If repeated dosing diminishes PD response, adjust either the interval length or administration frequency (e.g., more frequent dosing at lower amounts) rather than only increasing peak dose.
Serum stability–aware administration strategy (bolus vs. fractionated)
Because peptide activity may depend strongly on serum stability and cellular uptake, compare at least two exposure patterns: (A) a single bolus/pulse dose and (B) a fractionated schedule delivering the same or near-equivalent total daily amount (e.g., 2 administrations spaced 6–12 h apart). Apply this comparison in vitro and/or in vivo where sampling is possible. The goal is to identify whether sustained exposure is required to disrupt FOXO4 activation–dependent protein–protein interactions and to maintain downstream transcriptional suppression. Use PD sampling points that capture both early target engagement and later functional outcomes (e.g., transcriptional changes and apoptosis/viability) to guide the final regimen.